Skip to main content
. 2020 May 14;29(R1):R100–R106. doi: 10.1093/hmg/ddaa088

Figure 1.

Figure 1

Ex vivo genome editing with TALENs, ZFNs and CRISPR/Cas9 for autologous hematopoietic stem cell transplantation for beta-hemoglobinopathy patients.